Drug-maker Paragon Bioservices has agreed a $ about $602 million deal to acquire Maryland -based Gene therapies use specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition. The Wall Street Journal , according to a report in Catalent . The deal is expected to enable Catalent to pursue the development of specialised gene therapy treatments. Neither company has confirmed the report.
Drug-maker Paragon Bioservices has agreed a $ about $602 million deal to acquire Maryland -based The Wall Street Journal , according to a report in Catalent . The deal is expected to enable Catalent to pursue the development of specialised gene therapy treatments. Neither company has confirmed the report.